Cramer said Celgene is a reminder of the speculative nature of owning biotech stocks, especially those that rely on a single drug to prosper. He said he's still a believer in Celgene at these lower levels, albeit not as emphatically as before.
As for Onyx, Cramer said that company may still be a takeover target, but after the stock's big run up he's not willing to chase it higher.
--Written by Scott Rutt in Washington, D.C.
To contact the writer of this article, click here: Scott Rutt.To follow the writer on Twitter, go to http://twitter.com/scottrutt. To submit a news tip, send an email to: email@example.com. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts